[T CD4+淋巴细胞家族中最新的辅助性T细胞17亚群]

[The latest TH17 lymphocyte in the family of T CD4+ lymphocytes].

作者信息

Essakalli M, Brick C, Bennani N, Benseffaj N, Ouadghiri S, Atouf O

机构信息

Service de transfusion et d'hémovigilance de l'hôpital Ibn Sina, CHU Rabat, BP 2014, Rabat Ryad, Rabat, Maroc.

出版信息

Pathol Biol (Paris). 2010 Dec;58(6):437-43. doi: 10.1016/j.patbio.2009.01.001. Epub 2009 Mar 18.

DOI:10.1016/j.patbio.2009.01.001

PMID:19299092

Abstract

In recent years the T CD4+ lymphocyte family has grown. In the initial two components TH1 and TH2 lymphocytes were added the TH17 lymphocyte and T cell regulator (Treg). Under the influence of transforming growth factor β, interleukin 6 (IL6), IL21 and IL23, the naive lymphocyte T CD4+ differentiates in TH17. Currently, the TH17 is recognized as the leading actor of local inflammation through the pro-inflammatory cytokines (interleukins 17, 21, 22) that secretes and the expansion and recruitment of neutrophils that leads. Therefore, it is involved in chronic inflammatory processes, autoimmune diseases (rheumatoid arthritis, systemic lupus erythematosus), allergy and rejection of allogeneic transplants. TH17 lymphocyte opens up new therapeutic prospects for these pathologies.

摘要

近年来，T CD4+淋巴细胞家族不断壮大。最初的两个亚群TH1和TH2淋巴细胞之外，又增加了TH17淋巴细胞和调节性T细胞（Treg）。在转化生长因子β、白细胞介素6（IL6）、IL21和IL23的影响下，初始T CD4+淋巴细胞分化为TH17细胞。目前，TH17细胞通过分泌促炎细胞因子（白细胞介素17、21、22）以及导致中性粒细胞的扩增和募集，被认为是局部炎症的主要参与者。因此，它参与慢性炎症过程、自身免疫性疾病（类风湿性关节炎、系统性红斑狼疮）、过敏反应以及同种异体移植排斥反应。TH17淋巴细胞为这些疾病开辟了新的治疗前景。